Synthesis and biological evaluation of novel coumarin-chalcone derivatives containing urea moiety as potential anticancer agents

Kurt B., Kandas N. O., DAĞ A., Sonmez F., Kucukislamoglu M.

ARABIAN JOURNAL OF CHEMISTRY, vol.13, no.1, pp.1120-1129, 2020 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.1016/j.arabjc.2017.10.001
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Compendex, INSPEC, Directory of Open Access Journals
  • Page Numbers: pp.1120-1129
  • Keywords: Coumarin, Chalcone, Urea, Hepatoma, Antitumor, Cytotoxicity, Cell-cycle, Apoptosis, STANNOUS CHLORIDE, DESIGN, REDUCTION, ANTIOXIDANT, PREDICTION, COMPLEXES, ALCOHOLS, DOCKING, ARREST, AMINES
  • Bezmialem Vakıf University Affiliated: Yes


The increasing interest on new drug discovery is constantly up to date as drugs do not increase survival adequately against increasing cancer cases worldwide. Based on the reported anticancer activity of coumarin, chalcone and urea derivatives, the present investigation dealt with the design and synthesis of coumarin derivatives bearing diversely substituted chalcone-urea moieties 5a-k. Through a structure-based molecular hybridization approach, a series of novel coumarin-chalcone derivatives containing urea moiety was synthesized and screened for their in vitro antiproliferative activities against the cancer cell lines (H4IIE and HepG2). In addition, the synthesized compounds were tested on a cell line that was not cancerous (CHO) and the damage, it could give to normal cells was determined. Among the synthesized compounds, 5k exhibited better inhibition of H4IIE compared to Sorafenib. 5j also showed better inhibition against HepG2 than Sorafenib. In particular, 5k induced H4IIE apoptosis, arrested cell cycle at the S phase. Therefore, 5k and 5j may be potent antitumor agents, representing a promising lead for further optimization. (C) 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.